Home » Stocks » ETON

Eton Pharmaceuticals, Inc. (ETON)

Stock Price: $9.23 USD -0.20 (-2.12%)
Updated Jan 20, 2021 2:58 PM EST - Market open
Market Cap 228.33M
Revenue (ttm) 417,000
Net Income (ttm) -22.98M
Shares Out 21.05M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $9.23
Previous Close $9.43
Change ($) -0.20
Change (%) -2.12%
Day's Open 9.45
Day's Range 9.18 - 9.48
Day's Volume 210,311
52-Week Range 2.87 - 9.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments...

GlobeNewsWire - 1 month ago

Application Assigned a PDUFA Date of August 6, 2021 Application Assigned a PDUFA Date of August 6, 2021

GlobeNewsWire - 1 month ago

DEER PARK, Ill., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments ...

Seeking Alpha - 2 months ago

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

DEER PARK, Ill., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments ...

GlobeNewsWire - 3 months ago

- Application Assigned a PDUFA Date of May 29, 2021 - Application Assigned a PDUFA Date of May 29, 2021

GlobeNewsWire - 3 months ago

DEER PARK, Ill., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments ...

GlobeNewsWire - 3 months ago

DEER PARK, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments...

Zacks Investment Research - 3 months ago

Eton Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 3 months ago

- Application Assigned a PDUFA Date of May 27, 2021

GlobeNewsWire - 3 months ago

- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine

GlobeNewsWire - 3 months ago

-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children

Benzinga - 3 months ago

After an initial rejection in 2019 and a string of delays following a refiling of the regulatory application, Eton Pharmaceuticals Inc's ETON 1.47% out-licensed allergic conjunctivitis ophthal...

Other stocks mentioned: BHC
PRNewsWire - 3 months ago

LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Phar...

GlobeNewsWire - 4 months ago

DEER PARK, Ill., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug pro...

GlobeNewsWire - 4 months ago

DEER PARK, Ill., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug prod...

Seeking Alpha - 5 months ago

Eton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 17.86% and -93.85%, respectively, for the quarter ended June 2020.

Benzinga - 5 months ago

Shares of Eton Pharmaceuticals (NASDAQ:ETON) fell 1.5% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug prod...

GlobeNewsWire - 5 months ago

-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning

Seeking Alpha - 8 months ago

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -108.33% and -93.89%, respectively, for the quarter ended March 2020.

GlobeNewsWire - 8 months ago

DEER PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug produ...

Zacks Investment Research - 8 months ago

Eton Pharmaceuticals Inc (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

-Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product

Zacks Investment Research - 8 months ago

Eton Pharmaceuticals, Inc. (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Eton Pharmaceuticals

GlobeNewsWire - 9 months ago

-Estimated Market Opportunity of Greater than $100 Million

Zacks Investment Research - 9 months ago

Eton Pharmaceuticals, Inc. (ETON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 10 months ago

-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation

Seeking Alpha - 10 months ago

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 48.28% and -54.55%, respectively, for the quarter ended December 2019.

Seeking Alpha - 10 months ago

Eton Pharmaceuticals: Many Catalysts To Watch Out For In 2020

GlobeNewsWire - 11 months ago

DEER PARK, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug prod...

Zacks Investment Research - 11 months ago

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Other stocks mentioned: CLVS, IMMU, PRGO, VTVT
GlobeNewsWire - 11 months ago

DEER PARK, Ill., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug pro...

Seeking Alpha - 1 year ago

A Small Bet On Eton Pharmaceuticals

GlobeNewsWire - 1 year ago

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of  Phenylephrine ~

Seeking Alpha - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug prod...

24/7 Wall Street - 1 year ago

Eton Pharmaceuticals Inc. (NASDAQ: ETON) shares jumped on Tuesday after the firm announced that the U.S.

GlobeNewsWire - 1 year ago

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~

Zacks Investment Research - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 1 year ago

DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug pr...

Seeking Alpha - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Even after the recent sell-off, shares have risen by 15% since IPO pricing.

Zacks Investment Research - 1 year ago

Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

Benzinga - 1 year ago

Eton Pharmaceuticals (NASDAQ: ETON) shares are trading lower after the U.S Food and Drug Administration sent a Complete Response Letter to the company for EM-100.

Seeking Alpha - 1 year ago

Harrow Health holds large equity stakes in promising pre-clinical ophthalmology companies that aren't being factored into the current stock price.

About ETON

Eton Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ... [Read more...]

Industry
Biotechnology
IPO Date
Nov 13, 2018
CEO
Sean E. Brynjelsen
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ETON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ETON stock is "Buy." The 12-month stock price forecast is 14.00, which is an increase of 51.68% from the latest price.

Price Target
$14.00
(51.68% upside)
Analyst Consensus: Buy